| 10 | mg/kg bw/d | - | intravenous | rabbit | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 10 | mg/kg bw/day | - | oral | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 10 | mg/kg bw/d | - | oral | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 10 | mg/kg bw/d | - | oral | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| =10 | mg/kg bw/d | - | oral | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| =10 | mg/kg bw/d | - | oral | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 20 | - | - | oral | rabbit | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 40 | % | - | oral | rabbit | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 50 | mg/kg bw/ d | - | dermal | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 0.07979 | % | Concentration, 5% incidence of positive responses | Dermal | Human | NTP_ICE_skin_sensitization |
| 0.3661 | % | Concentration, 5% incidence of positive responses | Dermal | Human | NTP_ICE_skin_sensitization |
| 0.01064 | % | Concentration, one positive response | Dermal | Human | NTP_ICE_skin_sensitization |
| 0.03571 | % | Concentration, one positive response | Dermal | Human | NTP_ICE_skin_sensitization |
| =0.705 | mg/m3 | DNEL systemic | inhalation | Human | ToxValDB_GESTIS_DNEL |
| 2R97846T1L | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| 2R97846T1L | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| 2R97846T1L | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| 2R97846T1L | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| 17.07 | % | Incidence of positive responses | Dermal | Human | NTP_ICE_skin_sensitization |
| 31.33 | % | Incidence of positive responses | Dermal | Human | NTP_ICE_skin_sensitization |
| 625 | ug/cm2 | Induction dose per skin area | Dermal | Human | NTP_ICE_skin_sensitization |
| 968.8 | ug/cm2 | Induction dose per skin area | Dermal | Human | NTP_ICE_skin_sensitization |
| 99.73 | ug/cm2 | Induction dose per skin area, 5% incidence of positive responses | Dermal | Human | NTP_ICE_skin_sensitization |
| 283.7 | ug/cm2 | Induction dose per skin area, 5% incidence of positive responses | Dermal | Human | NTP_ICE_skin_sensitization |
| 13.3 | ug/cm2 | Induction dose per skin area, one positive response | Dermal | Human | NTP_ICE_skin_sensitization |
| 27.68 | ug/cm2 | Induction dose per skin area, one positive response | Dermal | Human | NTP_ICE_skin_sensitization |
| =70 | mg/kg bw | LD50 | oral | Rat | NTP_ICE_acute_oral |
| =138 | mg/kg bw | LD50 | oral | Rat | NTP_ICE_acute_oral |
| =275 | mg/kg bw | LD50 | oral | Rat | NTP_ICE_acute_oral |
| =290 | mg/kg bw | LD50 | oral | Rat | NTP_ICE_acute_oral |
| =306 | mg/kg bw | LD50 | oral | Rat | NTP_ICE_acute_oral |
| =221 | mg/kg bw/day | LEL | oral | Rat | ToxValDB_ECHA_IUCLID |
| =222 | mg/kg bw/day | LEL | oral | Rat | ToxValDB_ECHA_IUCLID |
| =225 | mg/kg bw/day | LEL | oral | Rat | ToxValDB_ECHA_IUCLID |
| =341 | mg/kg bw/day | LEL | oral | Rat | ToxValDB_ECHA_IUCLID |
| =382 | mg/kg bw/day | LEL | oral | Rat | ToxValDB_ECHA_IUCLID |
| =417 | mg/kg bw/day | LEL | oral | Rat | ToxValDB_ECHA_IUCLID |
| =3 | mg/kg bw/d | NOAEL | - | - | SCCS_vision_codex |
| =3 | mg/kg bw/d | NOAEL | - | - | SCCS_vision_codex |
| =3 | mg/kg bw/d | NOAEL | - | - | SCCS_vision_codex |
| =3 | mg/kg bw/d | NOAEL | - | - | SCCS_vision_codex |
| =9.6 | mg/kg bw/day | NOAEL | oral | Rat | ToxValDB_ECHA_IUCLID |
| =10 | mg/kg bw/day | NOAEL | oral | Rat | ToxValDB_ECHA_IUCLID |
| =10 | mg/kg bw/d | NOAEL | intravenous | rabbit | SCCS_vision_codex |
| =10 | mg/kg bw/day | NOAEL | oral | rat | SCCS_vision_codex |
| =10 | mg/kg bw/d | NOAEL | intravenous | rabbit | SCCS_vision_codex |
| =10 | mg/kg bw/day | NOAEL | oral | rat | SCCS_vision_codex |
| =10 | mg/kg bw/d | NOAEL | intravenous | rabbit | SCCS_vision_codex |
| =10 | mg/kg bw/day | NOAEL | oral | rat | SCCS_vision_codex |
| =10 | mg/kg bw/d | NOAEL | intravenous | rabbit | SCCS_vision_codex |